MOLECULAR PARTNERS AG
MOLNMolecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.
Drugs in Pipeline
13
Phase 3 Programs
3
Upcoming Catalysts
5
Next Catalyst
Oct 29, 2026
17dMarket Overview
Stock performance and key metrics
5 upcoming, 1 past
How MOLN's past catalysts played out
4D-150 IVT (3E10 vg/eye)
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 IVT (3x10^10 vg)
Diabetic Macular Edema (DME)
MP0420
COVID-19
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1
Leukemia
[212Pb]Pb-MP0712
Large Cell Neuroendocrine Carcinoma
4D-310
Fabry Disease
ATL-001 (Ciclopirox oral solution)
Congenital Erythropoietic Porphyria (CEP)
PMD-026
Metastatic Breast Cancer
Imatinib
Chronic Phase Chronic Myeloid Leukemia
MP0250
Neoplasms
4D-150 IVT
Neovascular (Wet) Age-Related Macular Degeneration
ensovibep
Covid19
MP0250 plus BOR+DEX
Multiple Myeloma in Relapse
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
4D-150 IVT (3E10 vg/eye) | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | - | - |
4D-150 IVT (3x10^10 vg) | Phase 3 | Diabetic Macular Edema (DME) | - | - |
MP0420 | Phase 3 | COVID-19 | - | - |
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 | Phase 2 | Leukemia | - | - |
[212Pb]Pb-MP0712 | Phase 2 | Large Cell Neuroendocrine Carcinoma | - | - |
4D-310 | Phase 2 | Fabry Disease | - | - |
ATL-001 (Ciclopirox oral solution) | Phase 2 | Congenital Erythropoietic Porphyria (CEP) | - | - |
PMD-026 | Phase 2 | Metastatic Breast Cancer | - | - |
Imatinib | Phase 2 | Chronic Phase Chronic Myeloid Leukemia | - | - |
MP0250 | Phase 2 | Neoplasms | - | - |
4D-150 IVT | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
ensovibep | Phase 2 | Covid19 | - | - |
MP0250 plus BOR+DEX | Phase 2 | Multiple Myeloma in Relapse | - | - |
Advanced biliary tract carcinoma (cholangiocarcinoma)
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MOLECULAR PARTNERS AG's drug pipeline?→
CatalystAlert tracks 13 drug candidates in MOLECULAR PARTNERS AG's (MOLN) pipeline across Phase 3, Phase 2. Its lead program is 4D-150 IVT (3E10 vg/eye) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MOLECULAR PARTNERS AG's next FDA catalyst?→
MOLECULAR PARTNERS AG's (MOLN) next tracked catalyst is a Earnings expected October 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MOLN biotech catalysts?→
Add MOLN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MOLECULAR PARTNERS AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.